Latest news with #Christophedombu
Business Insider
6 days ago
- Business
- Business Insider
MaaT Pharma (MAAT) Gets a Buy from Kepler Capital
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on June 2 and set a price target of €15.50. The company's shares closed yesterday at €5.64. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter dombu covers the Healthcare sector, focusing on stocks such as MaaT Pharma, Basilea Pharmaceutica, and Nyxoah. According to TipRanks, dombu has an average return of -9.3% and a 39.62% success rate on recommended stocks. Currently, the analyst consensus on MaaT Pharma is a Strong Buy with an average price target of €19.50. The company has a one-year high of €9.96 and a one-year low of €4.70. Currently, MaaT Pharma has an average volume of 7,961.
Business Insider
23-05-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Buy Rating on Nyxoah (NYXH)
Kepler Capital analyst Christophe dombu maintained a Buy rating on Nyxoah (NYXH – Research Report) on May 21 and set a price target of €14.50. The company's shares closed yesterday at $8.32. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, dombu is ranked #8607 out of 9537 analysts. Currently, the analyst consensus on Nyxoah is a Strong Buy with an average price target of $14.49, implying a 74.16% upside from current levels. In a report released on May 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $14.00 price target. The company has a one-year high of $11.87 and a one-year low of $5.55. Currently, Nyxoah has an average volume of 156K.
Business Insider
10-05-2025
- Business
- Business Insider
Kepler Capital Sticks to Their Buy Rating for arGEN X (0QW0)
Kepler Capital analyst Christophe dombu maintained a Buy rating on arGEN X (0QW0 – Research Report) on May 8 and set a price target of €730.00. The company's shares closed last Monday at €352.20. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, dombu is ranked #8514 out of 9472 analysts. Currently, the analyst consensus on arGEN X is a Strong Buy with an average price target of €673.63, which is a 91.26% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a €700.00 price target. Based on arGEN X's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €1.3 billion and a net profit of €835.54 million. In comparison, last year the company earned a revenue of €686.31 million and had a GAAP net loss of €155.63 million
